Curia Receives 2024 CDMO Leadership Award

Curia recognized for its Service in the CDMO industry

2024 CDMO Leadership Award
Curia Receives 2024 CDMO Leadership Award in the Service category.

ALBANY, N.Y., Feb. 05, 2024 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced it has been awarded a 2024 CDMO Leadership Award in the Service category, Small Pharma group. In its 13th year, the awards are presented by Outsourced Pharma and Life Science Leader.

“Curia is honored to receive this award,” said Philip Macnabb, CEO, Curia. “This distinction underscores our commitment to creating value for our customers across all of our R&D and manufacturing offerings, and we are especially appreciative to be acknowledged by the partners we support for that commitment.”

Winners of CDMO Leadership Awards are selected based on market research by Industry Standard Research (“ISR”) to distinguish CDMOs that meet or exceed customer expectations. For the 2024 awards, 98 contract manufacturers were evaluated by 23 performance metrics in ISR’s annual Contract Manufacturing Quality Benchmarking survey. Respondents to the survey only evaluate companies with which they have worked on an outsourced project within the past 18 months. Curia was awarded based on the feedback of respondents in the Small Pharma category.

“Congratulations to our 2024 CDMO Leadership Award winners. By vote of your customers, you are recognized as the best in the global outsourcing development and manufacturing sector of the biopharma industry,” says Louis Garguilo, Chief Editor and Conference Chair, Outsourced Pharma. “Award winners maintained and expanded capabilities and expertise to meet the needs of a diverse customer base; provided the additional quality and reliability so crucial to novel processes and products; and forged the closest relationships with customers. 2023 rang in with many unsettled questions. The 2024 CDMO Leadership Award winners are the support companies that best answered the bell over the past year.”

About Curia
Curia is a Contract Development and Manufacturing Organization (CDMO) with over 30 years of experience, an integrated network of 27 global sites and over 3,500 employees partnering with Biopharmaceutical customers to bring life-changing therapies to market. Our biologics and small molecules offering spans discovery through commercialization, with integrated regulatory and analytical capabilities. Our scientific and process experts and state-of-the-art facilities deliver best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to improve patients’ lives. Visit us at curiaglobal.com.

Corporate Contact:
Viana Bhagan
Curia
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/328a3a12-3a66-4a34-bdc8-e5de362efb85

GlobeNewswire Distribution ID 9031149

Curia reçoit le CDMO Leadership Award 2024

Curia est ainsi reconnue pour son service dans le secteur des organisations de développement et de fabrication sous contrat

ALBANY, New York, 05 févr. 2024 (GLOBE NEWSWIRE) — Curia, une organisation de développement et de fabrication sous contrat (CDMO) de premier plan, a annoncé aujourd’hui qu’elle avait reçu le CDMO Leadership Award 2024 dans la catégorie Service, groupe Small Pharma. Dans leur 13e année, les prix sont décernés par Outsourced Pharma et Life Science Leader.

« C’est un honneur pour Curia de recevoir ce prix », a déclaré Philip Macnabb, PDG de Curia. « Cette récompense souligne notre engagement à créer de la valeur pour nos clients dans l’ensemble de notre offre de R&D et de fabrication, et nous sommes particulièrement heureux de voir cet engagement reconnu par les partenaires que nous soutenons ».

Les lauréats des CDMO Leadership Awards sont sélectionnés sur la base d’une étude de marché réalisée par Industry Standard Research (« ISR ») afin de reconnaître les CDMO qui répondent aux attentes des clients, ou les dépassent. Pour le prix 2024, 98 fabricants sous contrat ont été évalués selon 23 indicateurs de performance dans l’enquête annuelle d’évaluation comparative de la qualité de la fabrication sous contrat menée par ISR. Les participants à l’enquête ont uniquement évalué les entreprises avec lesquelles ils ont travaillé sur un projet externalisé au cours des 18 derniers mois. Curia a été récompensée sur la base des commentaires des participants dans la catégorie Small Pharma.

« Félicitations aux lauréats du CDMO Leadership Award 2024. Par le vote de vos clients, vous êtes reconnus comme les meilleurs dans le secteur de l’externalisation du développement et de la fabrication de l’industrie biopharmaceutique », déclare Louis Garguilo, rédacteur en chef et président de la conférence, Outsourced Pharma. « Les lauréats ont maintenu et développé leurs capacités et leur expertise afin de répondre aux besoins d’une clientèle diverse ; ils ont fourni la qualité et la fiabilité supplémentaires si cruciales pour les nouveaux processus et produits ; et ils ont forgé les relations les plus étroites avec leurs clients. L’année 2023 a débuté par de nombreuses questions non résolues. Les lauréats du CDMO Leadership Award 2024 sont les entreprises sous-traitantes qui ont le mieux répondu à ces questions au cours de l’année écoulée ».

À propos de Curia
Curia est une organisation de développement et de fabrication sous contrat (CDMO) avec plus de 30 ans d’expérience, un réseau intégré de 27 sites dans le monde et plus de 3 500 collaborateurs travaillant en partenariat avec les clients biopharmaceutiques pour mettre sur le marché des thérapies qui changent la vie. Notre offre de produits biologiques et de petites molécules couvre le cycle complet de la découverte jusqu’à la commercialisation, avec des capacités réglementaires et analytiques intégrées. Nos scientifiques, nos experts en processus et nos installations de pointe apportent une expérience de premier ordre dans la fabrication de substances et de produits pharmaceutiques. De la curiosité au traitement, nous exécutons toutes les étapes pour améliorer la vie des patients. Consultez notre site à l’adresse www.curiaglobal.com.

Contact de l’entreprise :
Viana Bhagan
Curia
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Une photo accompagnant ce communiqué est disponible à l’adresse suivante : https://www.globenewswire.com/NewsRoom/AttachmentNg/328a3a12-3a66-4a34-bdc8-e5de362efb85

GlobeNewswire Distribution ID 9031542

Curia recebe CDMO Leadership Award de 2024

Curia reconhecida pelo seu serviço na indústria de CDMO

ALBANY, N.Y., Feb. 05, 2024 (GLOBE NEWSWIRE) — A Curia, uma organização líder em pesquisa, desenvolvimento e fabricação por contrato, anunciou hoje que recebeu um Prêmio de Liderança CDMO 2024 na categoria de Serviços do grupo Small Pharma. No seu 13º ano, os prêmios são apresentados pela Outsourced Pharma e Life Science Leader.

“A Curia recebe este prêmio com muita honra”, disse Philip Macnabb, CEO da Curia. “Essa distinção ressalta o nosso compromisso de criar valor para nossos clientes em todas as nossas ofertas de P&D e fabricação, e somos especialmente gratos por sermos reconhecidos pelos parceiros que apoiamos com a nossa dedicação.”

Os vencedores do CDMO Leadership Awards são selecionados com base nas pesquisas de mercado da Industry Standard Research (“ISR”) para homenagear as CDMOs que atendam ou excedam as expectativas dos clientes. Para as premiações de 2024, 98 fabricantes contratados foram avaliados com 23 métricas de desempenho na pesquisa anual de Benchmarking de Qualidade de Fabricação por Contrato da ISR. Os participantes da pesquisa avaliam apenas as empresas com as quais trabalharam em um projeto terceirizado nos últimos 18 meses. A Curia foi premiada com base no feedback dos participantes na categoria Small Pharma.

“Parabéns aos vencedores do Prêmio de Liderança CDMO 2024. Com o voto dos seus clientes, vocês foram reconhecidos como o melhor no setor global de desenvolvimento e fabricação terceirizada da indústria biofarmacêutica”, disse Louis Garguilo, Editor-Chefe e Presidente de Conferência da Outsourced Pharma. “Os vencedores do prêmio mantiveram e expandiram sua capacidade e conhecimento para atender às necessidades de uma base de clientes diversificada; forneceram a qualidade e confiabilidade adicionais tão cruciais para os novos processos e produtos; e estabeleceram relações mais próximas com os clientes. 2023 trouxe à tona muitas questões não resolvidas. Os vencedores do CDMO Leadership Award de 2024 são as empresas que mais deram suporte no ano passado.”

Sobre a Curia
A Curia é uma Organização de Desenvolvimento e Fabricação por Contratos (CDMO) com mais de 30 anos de experiência, uma rede integrada de 27 locais em todo o mundo e mais de 3.500 funcionários em parcerias com clientes biofarmacêuticos para lançar no mercado terapias que mudam a vida. Nossa oferta de produtos biológicos e pequenas moléculas abrange a descoberta através da comercialização, com capacidades regulatórias e analíticas integradas. Nossos especialistas científicos e de processos, e instalações de última geração oferecem a melhor experiência em fabricação de medicamentos e produtos farmacêuticos. Da curiosidade à cura, proporcionamos todas as etapas para a melhoria da vida dos pacientes. Visite-nos em curiaglobal.com.

Contato Corporativo:
Viana Bhagan
Curia
+1 (518) 512 2111
corporatecommunications@CuriaGlobal.com

Foto deste comunicado disponível em https://www.globenewswire.com/NewsRoom/AttachmentNg/328a3a12-3a66-4a34-bdc8-e5de362efb85

GlobeNewswire Distribution ID 9031542

Researchers at KFSH&RC & KAUST Discover Gene Responsible for Reproduction of the Most Dangerous Malaria Strain

Researchers at KFSH&RC & KAUST Discover Gene Responsible for Reproduction of the Most Dangerous Malaria Strain
King Faisal Specialist Hospital and Research Center – Riyadh

RIYADH, Saudi Arabia, Feb. 05, 2024 (GLOBE NEWSWIRE) — In a major scientific breakthrough, a research team from King Faisal Specialist Hospital and Research Centre (KFSH&RC), in collaboration with King Abdullah University of Science and Technology (KAUST), working alongside researchers from the UK, the US, and India, discovered a vital gene instrumental in combating malaria. This gene, termed PfAP2-MRP, is essential in the replication process of Plasmodium falciparum, the parasite that causes the most lethal strain of malaria.

Advanced laboratory techniques enabled the researchers to inhibit the PfAP2-MRP gene, revealing its critical role in the malaria parasite’s life cycle within red blood cells. This inhibition significantly disrupts the parasite’s ability to reproduce, reducing the severity of the disease’s symptoms and curbing its spread. This discovery is particularly impactful as it addresses Plasmodium falciparum malaria, which claims over half a million lives annually.

Dr. Ashraf Dada, Chairman of the Department of Pathology and Laboratory Medicine at King Faisal Specialist Hospital and Research Centre in Jeddah and the lead researcher, stated: “This discovery paves the way for the development of more effective treatments for the deadliest malaria strain, Plasmodium falciparum.” Also, this study enhances the scientific community’s understanding of the disease’s progression and its interaction with the human immune system, thereby strengthening efforts to combat this widespread malaria parasite prevalent in Africa.

Furthermore, the research demonstrated that the PfAP2-MRP gene regulates the production of genetically diverse protein receptors, allowing the parasite to evade the host’s immune system. This mechanism plays a significant role in the global spread of malaria and underscores the gene’s importance in developing future therapeutic strategies.

Published in the prestigious journal “Nature” this noteworthy study is part of a close collaboration between KFSH&RC and KAUST to engage in innovative research activities aimed at not only improving the diagnosis of microbes, bacteria, and parasites, but also underscores a global effort to combat pathogens and improve human health.

King Faisal Specialist Hospital and Research Centre stands among the global leaders in providing specialized healthcare, driving innovation, and serving as an advanced medical research and education hub. Through strategic partnerships with prominent local, regional, and international institutions, the hospital is dedicated to advancing medical technologies and elevating the standards of healthcare worldwide.

About King Faisal Specialist Hospital & Research Centre (KFSH&RC):

King Faisal Specialist Hospital & Research Centre (KFSH&RC) stands as a leading healthcare institution in the Middle East, envisioned to be the optimal choice for every patient seeking specialized healthcare. The hospital boasts a rich history in the treatment of cancers, cardiovascular diseases, organ transplantation, neurosciences, and genetics.

In 2023, “Brand Finance” ranked King Faisal Specialist Hospital & Research Centre as the top academic medical centre in the Middle East and Africa, and among the top 20 globally. Additionally, in 2022, it was recognized as one of the leading global healthcare providers by Newsweek magazine.

As part of Saudi Vision 2030, a royal decree was issued on December 21, 2021, to transform the hospital into an independent, non-profit, government-owned entity, paving the way for a comprehensive transformation program aimed at achieving global leadership in healthcare through excellence and innovation.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/38b3fbef-fece-4a76-b326-2d57ab1b16ba

CONTACT INFORMATION 

For more information please contact:

Mr. Essam Al-Zahrani, Media Affairs Head, 0555254429

Mr. Abdullah Al-Awn, Media Coordination Officer, 0556294232

GlobeNewswire Distribution ID 9031968

Blue California completes groundbreaking human clinical trial on ErgoActive® ergothioneine intervention for cognitive function, memory, and sleep

Rancho Santa Margarita, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) — Blue California, an industry leader in science-driven ingredient development, announced the successful completion of a groundbreaking human clinical trial of ergothioneine. A double-blinded placebo-controlled clinical trial sponsored by Blue California has shown that ErgoActive® ergothioneine supports aspects of cognitive function, memory, and sleep in healthy elderly subjects with subjective memory complaints.

“Blue California is proud to have sponsored such an important human study,” said Linda May-Zhang, Ph.D., VP of Science and Innovation at Blue California. “We are pleased by the results showing improvements of cognitive function and ability to get to sleep in subjects consuming ErgoActive for four months.”

Research has suggested that inadequate levels of ergothioneine are associated with a range of health problems, including cardiovascular disease, frailty, age-related cognitive decline, neurodegenerative diseases such as Parkinson’s disease, and dementias such as Alzheimer’s disease. Mushroom consumption and estimated dietary ergothioneine intake have previously been associated with reduced risk of cognitive decline and potentially longer lifespan.

Despite decades of preclinical research, association studies, and clinical studies conducted with mushrooms, it remained untested whether supplementation with pure ergothioneine can improve cognitive outcomes. Rigorous clinical studies were lacking. Today, Blue California has made a substantial advancement by sponsoring a double-blinded, placebo-controlled clinical study conducted at a national research institution.

Sharing his insights, Robert B. Beelman, Ph.D., Professor Emeritus of Food Science and Director of the Center for Plant and Mushroom Foods for Health at Pennsylvania State University, stated, “The results of this study provide important clinical evidence supporting the idea that ergothioneine is a ‘longevity vitamin’ that can help mitigate cognitive decline and sleep issues commonly associated with aging.”

Blue California is a proud gold sponsor for the National University of Singapore’s Center of Healthy Longevity global conference on Supplements for Healthy Longevity, held Feb. 29 – Mar. 2, 2024.

ErgoActive ergothioneine is made by precision fermentation with FDA-reviewed safety of GRAS. This ingredient is easy to formulate for dietary supplements, functional food and beverages, pet supplements, and cosmetics.

About Blue California Ingredients

Blue California is a science-driven, nature-inspired ingredient company dedicated to developing innovative solutions for health and well-being. We provide and manufacture clean, natural, and sustainable ingredients used in food, beverage, flavor, fragrance, dietary supplements, personal care, and cosmetic products.

With a commitment to rigorous scientific research, the company aims to address pressing concerns related to aging and healthspan.  For more information, visit https://bluecal-ingredients.com/ergothioneine.

ErgoActive® is a registered trademark of Blue California, Inc.

Ergothioneine is also referred to as L-Ergothioneine, (ET) and (ERG).

Attachments

Ana Capretz, Head of Public Relations and Communications
Blue California ingredients
+1-949-635-1991
ana@bluecal-ingredients.com

GlobeNewswire Distribution ID 9031565

Ghana’s Fintech Ecosystem takes centre-stage at Fintech Islands in Barbados


The vibrant landscape of Ghana’s FinTech industry has taken center-stage at the esteemed FinTech Islands event in Barbados.

A delegation from Ghana made up of Mr. Martin Kwame Awagah, President Ghana Fintech and Payments Association and Mr. Richard Nunekpeku, Vice President Legal and Strategy, represented Ghana’s digital finance ecosystem in Barbados.

Ghana’s active participation in the FinTech Islands event reinforces its commitment to driving innovation, fostering collaboration, and contributing to the global dialogue on financial technology.

The delegation’s engagements underscored the strides Ghana had made in embracing digital transformation to enhance financial services and promote inclusive economic growth.

The FinTech Islands event offers a platform where nations converge to share insights, collaborate, and shape the future of financial technology in the Caribbean. Ghana’s representation reflected the country’s standing as a key player in the global FinTech ecosystem.

Mr. Awagah, the Association
‘s President, kicked off the proceedings with a thought-provoking panel session on ‘Banking for All of Us: FinTech Innovation Driving Financial Inclusion.’

His insights shed light on Ghana’s commitment to leveraging technology to foster financial inclusion on a broader scale.

He delved into how government policies such as the National Financial Inclusion Development Strategy (NFIDS), Digital Financial Services Policy, and the Cashlite Roadmap have set the stage for the

country’s digital financial evolution.

‘These policies have tremendously transformed the delivery of financial services and we are even witnessing the offering of services in local languages, which is ensuring that financial access is not a barrier to the less educated.

These solutions are reaching millions of citizens across various sectors of the economy, thereby enhancing financial inclusion,’ he said.

The panel also included Mr. Zachary Harding Founding Partner, Delta Capital Partners – Caribbeann, Mr. Juan Zavala Aleman CEO and Co-Fo
under, FinZi – Columbia and Ms. Zia Paton PwC Partner, Digital Services – Caribbean.

Other officials from Ghana who participated in the panel discussion included Mr. Nunekpeku, the Vice President – Legal and Strategy Ghana Fintech and Payment Association.

He made a significant contribution to the discourse on ‘Fintechs Driving Adoption of Digital Money’ as the panel’s moderator.

On this panel were Adam Swartzbaugh, Founder and CEO of Almond Finance and Aldwyn Wayne, Founder and CEO, Colour Bank and WiPay.

Mr. Nunekpeku’s insights underscored the pivotal role that fintech companies played in driving the widespread adoption of digital currencies, such as crypto and stablecoins.

In another panel discussion, Mr. Awagah shared the stage with Mr. Kwame Oppong, Director of Fintech and Innovation at the Bank of Ghana, who joined in virtually, with Ms Carmelle Cadet, Founder and CEO of EMTECH, a renowned suptech platform at the forefront of digitizing regulatory processes,

The panel engaged in a compelling discu
ssion titled ‘CBDC Masterclass: Lessons Learned from the eCedi Hackathon.’

This insightful session delved into the intricacies of Central Bank Digital Currency (CBDC) implementation, drawing lessons from Ghana’s groundbreaking eCedik.

Source: Ghana News Agency

Recovery or Recession? – Three Questions about China’s Economy


For some time, there have been some commentary in the international community that speak ill of China’s economy.

What is the trend of China’s economy?

Recently, the National Bureau of Statistics of China has published the statistics about China’s national economic performance in 2023.

It shows that China’s economy has rebounded and moved upward, with high-quality development solidly advancing, new economic drivers developing faster, market demand recovering steadily, green transformation forging ahead, and foreign trade becoming more resilient.

China’s economy will continue to provide strong impetus for the world.

Is China’s economy stagnating? As shown by the statistics, China’s economy is making steady progress, and remains the biggest engine of global growth.

The International Monetary Fund has stated that China will be the largest driver of global economic growth in the next five years, and one percentage point increase in gross domestic product (GDP) growth in China leads to 0.3 percentage point i
ncrease in growth in other economies.

As the only country encompassing all industrial categories in the United Nations industrial classification, China contributes to around one-third of world economic growth over the years.

The scale of China’s manufacturing industry has ranked first in the world for 13 consecutive years.

In 2023, the Chinese economy has achieved a year-on-year GDP growth of 5.2 per cent, outpacing most major economies.

China is now advancing Chinese modernisation on all fronts through high-quality development, delivering modernisation to more than 1.4 billion people.

It will be a remarkable achievement in human history, one that will provide continuous impetus to the development of China and the wider world.

Will China’s declining population pose economic challenges?

China’s demographic dividend is turning into talent dividend, as innovation is the primary driving force for development.

China now ranks first in the world in terms of the size of talent pool, human resources in scienc
e and technology and the total number of researchers.

China’s industrial optimisation and upgrading has achieved remarkable results and is moving up the mid-to-high-end value chain.

China’s expenditure on research and development and investment in high-tech industries have maintained double-digit growth for many years.

The number of China’s patent applications ranks first in the world, and the number of unicorn companies ranks second in the world.

China is pushing ahead green and low-carbon transformation, which will provide impetus for development in green infrastructure, green energy, green transportation and other fields, and generate a market of 10 trillion yuan per year.

Is China’s Door closing?

China remains firmly committed to opening up, sharing development opportunities with the world.

President Xi Jinping’s call for high-quality Belt and Road cooperation and the Global Development Initiative have provided the most inclusive and extensive international cooperation platform.

China is the major
trading partner of more than 140 countries and regions.

Our overall tariff level has been cut to 7.3 per cent, relatively at par with the developed members in the World Trade Organisation.

China is the world’s largest source of international development financing.

Since the beginning of this century, China has provided approximately $1.34 trillion in loans and grants to more than 20,000 projects in 165 low- and middle-income countries.

By opening up wider, China aims to develop together with all in the world.

Recently, there are some negative rhetoric against China’s economy.

Some countries want to shut out China in the name of ‘de-risking’, to ‘decouple’ from China, fragment industrial and supply chains, and build ‘small yards with high fences’.

However, facts speak louder than words. In the post-epidemic era, despite challenging international environment, increasing uncertainty of the world economy and insufficient growth momentum, China’s economy can still achieve its growth targets beyond expectati
ons with per capita disposable income continuing to rise, which is a strong demonstration of China’s resilience, vitality and potential.

To shut out China is to throw away opportunities, cooperation, stability and development.

Such a move would only create and spread risks, and no one would benefit from it.

As Premier Li Qiang has stated in the special address at the Opening Ceremony of the World Economic Forum Annual Meeting 2024, the world has entered a new period of turbulence and transformation, yet the overall direction of human development and progress will not change, the overall dynamics of world history moving forward amid twists and turns will not change, and the overall trend toward a shared future for the international community will not change.

After all the shifts and changes over the years, all should cherish communication the more and exchange, solidarity and cooperation, openness and sharing, peace and stability, forging ahead with a shared aspiration for a better future toward building a
community with a shared future for mankind!

Source: Ghana News Agency

Two siblings arrested for disturbing court sittings


Safianu Osumanu and Aishatu Osuman, two siblings who disrupted court sittings at the Ashiaman District Court, have been arrested by the Ashaiman police.

The two who accompanied their mother, Hamdiya Inusah, a landlady who has a case at the court, were arrested, handcuffed, and sent to the Ashiaman Divisional Police Headquarters after court proceedings.

Osuman, who stood up and started talking in the courtroom while the presiding judge, Mr Derick Eshun Parden, was giving his verdict on their mother’s case, was ushered outside by the police officer attached to the court after some resistance from him.

He, together with his sister, however, pushed and held the uniform of Inspector Tetteh Nartey, the prosecutor, hurling insults at him and alleging that he had taken a bribe from the complainant in their mother’s case.

Meanwhile, in the substantive case, the court heard that Inusah rented a room to a tenant at a cost of GHS2,400 for a number of years.

The prosecution said the tenant, who is the complainant in
the case, vacated the room before the expiration of the tenancy agreement following a misunderstanding between them and demanded a refund of the money paid.

Inusah paid GHS 400 out of the money after the tenant reported the case to the Rent Control Department.

The prosecutor said the case was subsequently put before the court after her refusal to refund the remaining money.

The court therefore ordered Inusah to pay GHS 2,000 to the complainant and an additional GHs 500 in costs to the court.

Source: Ghana News Agency